A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill received ...
Vertex Pharmaceuticals is ahead of schedule, filing a new drug application for its next-gen cystic fibrosis (CF) treatment dubbed vanza triple. Vertex completed the regulatory submission a month ...
Each year, around 80 million Americans are prescribed a medicine for moderate to severe pain. Journavx is the first new type of painkiller approved in more than 20 years. It prevents pain signals from ...
Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain, sickle cell disease, beta thalassemia, and type 1 diabetes, with approved products in each area. Suzetrigine ...
Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) ...
Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results